Go Pro
→ SpaceX is NOT the #1 IPO of 2026 (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.21
+2.7%		$24.39
$19.69
▼
$29.48
$5.03B0.811.68 million shs1.78 million shs
Alvotech stock logo
ALVO
Alvotech
$3.81
+0.3%		$3.61
$2.94
▼
$9.25
$1.15B0.18814,003 shs342,028 shs
Celcuity, Inc. stock logo
CELC
Celcuity
$92.79
-0.5%		$94.57
$44.16
▼
$151.02
$4.52B0.21.70 million shs543,219 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$34.98
-1.7%		$29.99
$24.51
▼
$36.82
$4.13BN/A438,193 shs279,770 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+2.67%+12.91%+12.35%+30.40%+22.73%
Alvotech stock logo
ALVO
Alvotech
+0.26%-7.52%+12.06%+16.87%-54.96%
Celcuity, Inc. stock logo
CELC
Celcuity
-0.49%+7.42%-14.79%-29.20%+109.98%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-1.69%+2.94%+13.46%+3,497,999,900.00%+3,497,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.21
+2.7%		$24.39
$19.69
▼
$29.48
$5.03B0.811.68 million shs1.78 million shs
Alvotech stock logo
ALVO
Alvotech
$3.81
+0.3%		$3.61
$2.94
▼
$9.25
$1.15B0.18814,003 shs342,028 shs
Celcuity, Inc. stock logo
CELC
Celcuity
$92.79
-0.5%		$94.57
$44.16
▼
$151.02
$4.52B0.21.70 million shs543,219 shs
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$34.98
-1.7%		$29.99
$24.51
▼
$36.82
$4.13BN/A438,193 shs279,770 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+2.67%+12.91%+12.35%+30.40%+22.73%
Alvotech stock logo
ALVO
Alvotech
+0.26%-7.52%+12.06%+16.87%-54.96%
Celcuity, Inc. stock logo
CELC
Celcuity
-0.49%+7.42%-14.79%-29.20%+109.98%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
-1.69%+2.94%+13.46%+3,497,999,900.00%+3,497,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.82
Moderate Buy$33.4414.49% Upside
Alvotech stock logo
ALVO
Alvotech
2.00
Hold$7.6099.48% Upside
Celcuity, Inc. stock logo
CELC
Celcuity
2.82
Moderate Buy$155.1867.24% Upside
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
3.00
Buy$41.6719.12% Upside

Current Analyst Ratings Breakdown

Latest ALVO, ACAD, CELC, and PBLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$36.00 ➝ $37.00
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$23.00 ➝ $25.00
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$35.00 ➝ $36.00
7/29/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
7/29/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.50
7/21/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$34.00 ➝ $36.00
7/21/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$24.00 ➝ $25.00
7/15/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$178.00
7/15/2026
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $155.00
(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.70$0.89 per share32.93$7.58 per share3.85
Alvotech stock logo
ALVO
Alvotech
$588.90M1.95$0.22 per share17.48($0.94) per share-4.05
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2213.1629.5117.1933.42%9.03%6.79%N/A
Alvotech stock logo
ALVO
Alvotech
$27.92M-$0.25N/A11.91N/A-14.36%-11.92%-7.59%8/19/2026 (Estimated)
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$3.90N/A4,639.50N/AN/A-244.61%-50.22%8/13/2026 (Estimated)
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest ALVO, ACAD, CELC, and PBLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
Alvotech stock logo
ALVO
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16N/AN/AN/A$4.42 millionN/A
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
5/14/2026Q1 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.48
Alvotech stock logo
ALVO
Alvotech
N/A
1.76
0.88
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
12.31
12.31
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Alvotech stock logo
ALVO
Alvotech
N/A
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Alvotech stock logo
ALVO
Alvotech
0.46%
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
Alvotech stock logo
ALVO
Alvotech
1,460301.81 million300.42 millionNot Optionable
Celcuity, Inc. stock logo
CELC
Celcuity
4048.77 million42.27 millionOptionable
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
N/A118.15 millionN/AN/A

Recent News About These Companies

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-inc-nasdaqpbls-given-average-recommendation-of-buy-by-analysts-2026-08-01/
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest
July 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-inc-nasdaqpbls-sees-significant-increase-in-short-interest-2026-07-14/
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS)
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-incs-quiet-period-set-to-expire-on-july-20th-nasdaqpbls-2026-07-13/
Parabilis Medicines (NASDAQ:PBLS) Rating Increased to Hold at Zacks Research
July 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/parabilis-medicines-nasdaqpbls-rating-increased-to-hold-at-zacks-research-2026-07-09/
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
July 6, 2026  |  benzinga.comhttps://www.benzinga.com/news/26/07/60274173/this-parabilis-medicines-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday?utm_source=snapi
PBLS Parabilis Medicines, Inc.
July 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/PBLS/sec-filings
Guy Levy Acquires 500,000 Shares of Parabilis Medicines (NASDAQ:PBLS) Stock
June 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbls-insider-buying-and-selling-2026-06-30/
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
June 27, 2026  |  fool.comhttps://www.fool.com/investing/2026/06/27/this-little-known-biotech-just-delivered-a-bigger/
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
June 20, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/20/fresh-off-ipo-a-director-buys-usd474-000-of-parabilis-medicines-stock-is-pbls-a-buy/
Insider Buying: Parabilis Medicines (NASDAQ:PBLS) Director Acquires 8,435 Shares of Stock
June 17, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbls-insider-buying-and-selling-2026-06-17/
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
June 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/parabilis-medicines-pbls-stock-valuation-211405848.html
StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO
June 14, 2026  |  genengnews.comG
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/parabilis-medicines-announces-closing-upsized-200500345.html
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials
May 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4908000-parabilis-medicines-starts-ipo-on-promising-cancer-therapy-trials

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.21 +0.76 (+2.67%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$28.86 -0.36 (-1.22%)
As of 08/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Alvotech stock logo

Alvotech NASDAQ:ALVO

$3.81 +0.01 (+0.26%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$3.78 -0.03 (-0.79%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Celcuity stock logo

Celcuity NASDAQ:CELC

$92.79 -0.46 (-0.49%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$92.75 -0.04 (-0.04%)
As of 08/7/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Parabilis Medicines stock logo

Parabilis Medicines NASDAQ:PBLS

$34.98 -0.60 (-1.69%)
As of 08/7/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas